New insights into the dule roles CDK12 in human cancers: Mechanisms and interventions for cancer therapy.
10.1016/j.jpha.2024.101173
- Author:
Wei DAI
1
;
Dong XIE
2
;
Hao HUANG
1
;
Jingxuan LI
2
;
Caiyao GUO
3
;
Fuqiang CAO
1
;
Luo YANG
4
;
Chengyong ZHONG
5
;
Shenglan LIU
1
Author Information
1. Jiangxi Province Key Laboratory of Pharmacology of Traditional Chinese Medicine, School of Pharmacy, Gannan Medical University, Ganzhou, Jiangxi, 341000, China.
2. Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Ministry of Education, Jiangxi Provincial Key Laboratory of Tissue Engineering, School of Rehabilitation Medicine, Gannan Medical University, Ganzhou, Jiangxi, 341000, China.
3. Department of Rehabilitation, The Second Affiliated Hospital of Zhejiang University, Hangzhou, 310051, China.
4. State Key Laboratory of Ophthalmology, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, 510060, China.
5. Department of Pathology, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, 341000, China.
- Publication Type:Review
- Keywords:
CDK12;
Oncogene;
Targeted therapy;
Tumor suppressor
- From:
Journal of Pharmaceutical Analysis
2025;15(7):101173-101173
- CountryChina
- Language:English
-
Abstract:
The dysregulation of cyclin-dependent kinase 12 (CDK12), which may result from genomic alterations or modulation by upstream effectors, is implicated in cancer oncogenesis and progression. CDK12 overexpression or activation is sufficient to induce tumor initiation, recurrence, and therapeutic resistance. However, CDK12 may also exert tumor-suppressive functions in a context-dependent manner. Therefore, caution is warranted when targeting CDK12 in future clinical trials. A comprehensive elucidation of the dual roles and underlying mechanisms of CDK12 in carcinogenesis is urgently needed to advance precision oncology. This review provides an overview of the current understanding of the dysregulation and biological roles of CDK12 in cancer. Subsequently, we systematically summarize the functions and mechanisms of the oncogenic and tumor-suppressive roles of CDK12 in different contexts. Finally, we discuss the potential of CDK12 as a novel therapeutic target and its implications in clinical oncology, offering insights into future directions for innovative cancer treatment strategies.
